Glucotrace (Fludeoxyglucose (18f))

Glucotrace is employed in PET imaging to assess metabolic activity in several clinical contexts. It supports diagnostic decision‑making by highlighting areas of increased glycolysis.

• Oncologic PET imaging for tumor detection, staging, and monitoring therapeutic response.
• Cardiac PET imaging to evaluate myocardial viability and perfusion.
• Neurologic PET imaging for epilepsy focus localization, dementia assessment, and brain tumor evaluation.
• Research applications investigating metabolic pathways in experimental settings.

Adverse reactions to Glucotrace are generally infrequent, but they can be categorized by frequency and severity.

Common

• Mild injection site discomfort or erythema.
• Transient nausea or vomiting.
• Temporary headache.
• Low‑grade fever.
• Brief dizziness or light‑headedness.

Serious

• Allergic reactions ranging from urticaria to anaphylaxis.
• Severe hypotension or cardiovascular collapse.
• Acute renal impairment in patients with pre‑existing kidney disease.
• Radiation‑related tissue injury in high‑dose exposure scenarios.

Glucotrace should be administered with consideration of patient‑specific factors and institutional safety protocols.

• Verify pregnancy status; the radiopharmaceutical is contraindicated in known or suspected pregnancy due to fetal radiation exposure.
• Assess renal function before injection, as impaired clearance may increase radiation dose.
• Ensure proper hydration to facilitate renal excretion of the tracer.
• Follow radiation safety guidelines for staff, including shielding and exposure monitoring.
• Review patient history for prior allergic reactions to radiopharmaceuticals.
• Maintain accurate documentation of administered activity and timing for image interpretation.

Glucotrace may interact with other substances that affect glucose metabolism or radiation exposure.

Avoid

• Concurrent administration of high‑dose glucose or insulin that could alter tracer uptake patterns.
• Use of other radiopharmaceuticals within 24 hours, which may increase cumulative radiation dose.

Use with caution

• Medications that modify glycolysis, such as metformin, may affect image quality.
• Contrast agents used in CT may influence PET/CT interpretation.
• Chemotherapeutic agents that cause rapid tumor cell turnover could alter tracer distribution.
• Beta‑blockers or other cardiovascular drugs that impact myocardial perfusion.
• Any drug that significantly changes blood glucose levels around the time of imaging.